• Alto Neuroscience posted a Q2 net loss of $27.64 million; loss per share was $0.65, unchanged from a year earlier.
• R&D expense rose 68.43% to $22.11 million; G&A expense increased 26.32% to $7.02 million.
• Cash, cash equivalents and restricted cash totaled $244.23 million at June 30; pro forma cash was about $338 million after a July offering.
• July registered direct offering sold 3,776,436 shares at $26.48 for $100 million gross, $94.6 million net to expand ALTO-207 development.
• ALTO-207 Phase 2b PACE-1 data expected in 2H 2027; Phase 3 PACE-2 starts early 2027, monotherapy Phase 3 planned 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812450316) on August 12, 2026, and is solely responsible for the information contained therein.